Molecular Weight of Semaglutide: Analytical Mass, Chemical Structure, and Laboratory Calculations

Direct Answer: What Is the Molecular Weight of Semaglutide?

The molecular weight of semaglutide is 4113.58 g/mol (Daltons) for its monoisotopic mass, with an average molecular weight of approximately 4113.64 Da depending on isotopic distribution. Its empirical chemical formula is C187H291N45O59. Semaglutide is a modified 31-amino-acid synthetic peptide conjugated to a C18 fatty diacid side chain via a hydrophilic spacer.

For investigators performing quantitative analytical assays, accurate determination of this molecular mass is critical when preparing micromolar or nanomolar concentration stock solutions from lyophilized samples of the semaglutide research compound. The precise addition of the fatty acid diacid moiety significantly increases the compound's overall molecular weight compared to native human GLP-1 (7-37), which possesses a molecular weight of 3297.68 Da.

Chemical Formula and Structural Architecture

Semaglutide is engineered based on the sequence of human glucagon-like peptide-1 (GLP-1), but incorporates three deliberate structural modifications that alter both its molecular weight and enzymatic stability profile. Understanding these modifications clarifies how the final mass of 4113.58 g/mol is derived.

First, at position 8, native L-alanine is replaced by 2-aminoisobutyric acid (Aib). This non-proteinogenic amino acid substitution prevents cleavage by dipeptidyl peptidase-4 (DPP-4) without altering receptor affinity. Second, at position 34, lysine is substituted with arginine to ensure mono-acylation occurs selectively at position 26. Third, the lysine residue at position 26 is acylated with a linker consisting of a gamma-glutamic acid (γ-Glu) spacer and two 8-amino-3,6-dioxaoctanoic acid (OEG/mini-PEG) units, attached to a C18 fatty diacid (octadecanedioic acid).

The addition of this hydrophobic C18 diacid tail and hydrophilic OEG spacer contributes 675.84 Da to the peptide core backbone, resulting in the total calculated mass of 4113.58 g/mol. In vitro assays demonstrate that this specific acylation design allows non-covalent binding to serum albumin, extending the half-life of the compound during preclinical evaluation.

Mass Spectrometry Verification and Analytical Identification

In modern peptide synthesis and laboratory quality control, confirming the molecular weight of semaglutide via Liquid Chromatography-Mass Spectrometry (LC-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry is the definitive method for identity verification.

When analyzing high-purity semaglutide samples on an Electrospray Ionization (ESI) mass spectrometer, the primary observed signals represent multiply charged protonated ions rather than a single uncharged peak. Common m/z signals observed in positive mode mass spectra include:

- [M+3H]3+: ~1372.2 m/z

- [M+4H]4+: ~1029.4 m/z

- [M+5H]5+: ~823.7 m/z

Deconvolution of these multicharged spectral peaks yields the true monoisotopic mass of 4113.58 Da. Research facilities verifying raw material quality must ensure that no secondary truncated peptide peaks (e.g., des-Aib or unacylated peptide backbones) are present in significant quantities on the LC-MS chromatogram. Reviewing raw analytical spectrum files via PX1 Research's analytical research portal provides confirmation of lot-specific molecular purity.

Calculations for Molar Concentration and Reconstitution

When preparing stock solutions for in vitro receptor binding assays or cell culture studies, laboratory researchers must use the exact molecular weight of 4113.58 g/mol to calculate molar concentrations correctly. Standard weight-to-volume preparations without adjusting for molecular mass can lead to significant experimental error.

The basic formula for determining the required mass ($m$) for a target molar concentration ($C$) in volume ($V$) is:

$$m (grams) = C (mol/L) \times V (L) \times 4113.58 (g/mol)$$

For example, to prepare 10 mL of a 100 µM (0.0001 M) stock solution of semaglutide:

$$m = 0.0001 \text{ mol/L} \times 0.010 \text{ L} \times 4113.58 \text{ g/mol} = 0.00411358 \text{ g} = 4.114 \text{ mg}$$

Thus, exactly 4.114 mg of pure peptide free base is required per 10 mL of solvent to achieve a 100 µM concentration. Investigators utilizing our comprehensive peptide reconstitution guide can reference standard dilution protocols adjusted for peptidic net content and counter-ion mass corrections.

Comparative Analysis of Incretin Research Peptides

Within preclinical metabolic research, several metabolic and incretin mimetic peptides are routinely compared alongside semaglutide. Understanding their distinct molecular weights and chemical structures is essential when designing comparative cell line or tissue assays.

As shown below, variations in amino acid sequence length, fatty acid acylation chemistry, and multi-receptor co-agonism dramatically alter the molecular mass across different glp-1 receptor agonists:

The dual GLP-1/GIP receptor agonist tirzepatide has a molecular weight of 4813.45 g/mol, incorporating a 39-amino-acid backbone acylated with a C20 fatty diacid. The triple agonist retatrutide exhibits a molecular weight of 4731.33 g/mol. Meanwhile, early-generation analogues such as those evaluated in liraglutide research feature a lower molecular weight of 3751.20 g/mol due to a shorter C16 single-chain fatty acid acylation without the dual OEG mini-PEG spacer. Researchers can source all of these analytical-grade reference materials through the main PX1 catalog of research peptides.

Physical Properties, Isoelectric Point, and Solubility Parameters

Beyond molecular weight, the physical behavior of semaglutide in aqueous solution is dictated by its primary sequence charges and the chemical nature of its C18 side chain. Semaglutide exhibits an estimated theoretical isoelectric point (pI) of approximately 4.2 to 4.5, primary driven by the terminal carboxylic acid groups and the gamma-glutamic acid side-chain modifications.

At neutral physiological pH (7.4), semaglutide carries a net negative charge, which enhances solubility in standard phosphate-buffered saline (PBS) or dilute aqueous buffers. However, near its isoelectric point (pH 4.0–5.0), solubility drops significantly, and precipitation or self-association into oligomeric states can occur.

Because of its amphiphilic structure—combining a polar peptide backbone with a hydrophobic C18 fatty acid chain—semaglutide acts as a weak surfactant in solution and can form self-assembled hydrophobic multimeric complexes at concentrations exceeding its critical micelle concentration. Researchers evaluating peptide physical characteristics must control pH, ionic strength, and temperature to avoid non-specific aggregation during analytical assays.

Quality Verification: HPLC, Mass Spectrometry, and Endotoxin Control

Because small impurities or incorrect acylation steps during solid-phase peptide synthesis (SPPS) can dramatically affect binding kinetics and experimental outcomes, rigid quality control standards must be applied to every production lot.

PX1 Research implements a comprehensive quality verification process for all compounds synthesized for laboratory investigation:

- **High-Performance Liquid Chromatography (RP-HPLC):** Verifies chemical purity to ensure a minimum threshold of ≥99.0% peak area integration.

- **Mass Spectrometry (LC-MS):** Confirms the precise target molecular weight of 4113.58 Da and detects any truncated deletion sequences.

- **Endotoxin Analysis (LAL Assay):** Ensures endotoxin levels remain below strictly defined laboratory limits (<0.01 EU/mg), preventing confounding inflammatory artifacts in cell-based assays.

- **Lot-Specific Certificate of Analysis (COA):** Every single lot is verified by independent, accredited ISO 17025 third-party laboratories within the United States.

Institutional purchasing agents and laboratory managers requiring high-volume analytical reagents can access our bulk lab account services for batch-level documentation and standardized batch testing metrics.

Laboratory Storage, Handling, and Stability Guidelines

To preserve the structural integrity and prevent hydrolytic or oxidative degradation of the 4113.58 Da molecule, strict laboratory handling procedures must be followed upon receiving lyophilized semaglutide.

Lyophilized semaglutide powder should be stored long-term at -20°C to -80°C in a desiccated environment protected from light exposure. Under these conditions, the peptide remains stable for extended periods without significant cleavage of the C18 side chain or oxidation of methionine residues.

Upon reconstitution with sterile bacteriostatic water or laboratory-grade aqueous buffer (pH 7.4), working aliquots should be stored at 2°C to 8°C for short-term evaluation or frozen in single-use aliquots at -80°C to prevent repeated freeze-thaw cycles. Repeated thermal cycling accelerates aggregation of the acylated peptide chains, altering effective solution concentration.